We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

HighRes Biosolutions to Implement Flexible Laboratory Automation System at IRBM Science Park, Italy

Rectangle Image
Product News

HighRes Biosolutions to Implement Flexible Laboratory Automation System at IRBM Science Park, Italy

IRBM Science Park (Pomezia, Italy) has selected HighRes Biosolutions to supply a flexible NanoCell™ laboratory automation system.

The NanoCell will be installed as IRBM updates its high-throughput screening infrastructure to support the Italian Chemical Collection and Screening Initiative, a collaboration with Italian state research institutions.

The NanoCell system will automate biochemical and cell-based high-throughput screening (HTS) assays to support small-molecule drug discovery.

In IRBM’s NanoCell system three MicroDocks™, HighRes’ patented docking stations, surround the central robotic arm.

IRBM’s existing lab instruments (e.g., plate readers, dispensers, incubators) will be mounted on mobile carts that dock and undock from the robotic work cell via any of the MicroDocks, which precisely align the instrument carts for robotic access, and automatically supply power, data and gases. Docking and undocking take less than 30 seconds and are completely automatic.

“As a contract screening service provider, the key to our decision to work with HighRes Biosolutions was the unlimited flexibility that the MicroDock stations give to our NanoCell automation system,” said Alberto Bresciani, Head of Screening Technologies at IRBM Science Park.

Bresciani continued, “In the future we will be able to efficiently support multiple experiment and reader end-point formats by simply swapping different instrument carts on and off the system as needed.”

“We are very pleased to be working with IRBM in Italy,” said Jack Dawson, Business Director Europe at HighRes Biosolutions.

Dawson continued, “IRBM is a great example of how small private research enterprises can provide highly relevant services in these challenging times for pharmaceutical drug discovery. The built-in flexibility of our NanoCell system helps ensure that IRBM’s investment in automation for high-throughput screening will stay relevant for many years to come, growing and adapting as their services and requests change over time”.

Advertisement